<DOC>
	<DOCNO>NCT02891083</DOCNO>
	<brief_summary>Histological Node Negative thoracic esophageal squamous cell carcinoma（pN0 ESCC） radical resection still carry risk recurrence complete surgical resection , especially high-risk patient . There still lack knowledge postoperative treatment indication method pN0 ESCC.Our previous study show risk recurrence associate location cell differentiation primary tumor , well presence lymphovascular invasion . This project design study efficacy adjuvant therapy patient pN0 ESCC mention risk factor recurrence radical surgery . We aim compare difference among adjuvant chemotherapy , adjuvant radiotherapy , surgery alone pN0 ESCC prospective randomize controlled trial . There similar study esophageal cancer previously report similar design . The result study expect high clinical relevance .</brief_summary>
	<brief_title>Adjuvant Therapies Surgery Alone High Risk pN0 Esophageal Cancer</brief_title>
	<detailed_description>The study design prospective randomize controlled trial , aim compare impact adjuvant chemotherapy Paclitaxel Cisplatin , adjuvant radiotherapy IMRT 50Gy , surgery alone disease free survival ( DFS ) patient high-risk pN0 thoracic esophageal squamous cell carcinoma . Pathological stag base 7th UICC edition , radical resection systemic lymph node dissection , accurate staging.Patients pT1b-T4a disease , prove pN0 upon pathological examination , meet least one risk factor inclusion criterion , without exclusion criterion randomize one three study arms.Definition high-risk factor recurrence include : ( 1 ) Tumor location : middle upper third thoracic esophagus ; ( 2 ) Presence LVI submucosal metastasis ; ( 3 ) Cell differentiation : poorly differentiate undifferentiated . Primary endpoint : To observe compare Disease-Free Survivals ( DFS ) among three study arm . Secondary endpoint : To observe compare Overall Survivals ( OS ) among three study arm , compare adverse event adjuvant chemotherapy adjuvant radiation group . Additional instruction : No .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patient : No pretreatment surgery.Informed consent sign screening ; 2 . Surgery : Complete ( R0 ) resection tumor , thoraco abdominal twofield cervicothoracoabdominal threefield lymph node dissection transthoracic esophagectomy . At least 12 station 12 lymph node harvest , include bilateral recurrent laryngeal nerve node . Both open thoracotomy minimally invasive thoracoscopic/laparoscopic approach allow histopathological examination confirm diagnosis patient least clean equal 12 station 12 lymph node ; 3 . Histology : Thoracic esophageal squamous cell carcinoma , nodal involvement ( pN0 ) pathological examination ; 4 . Staging : Tumor T stage T1bT4a accord 7th UICC esophageal cancer stag system ; 5 . Definition high risk recurrence : meet least one three . A : Primary tumor locate middle upper third thoracic esophagus B : Presence lymphovascular invasion ( LVI ) submucosal metastasis C : Cell differentiation : Low grade undifferentiated 6 . Performance status : ECOG score 02 ; 7 . Cardiac function : NYHA classification 12 . Normal electrocardiogram ; 8 . Renal function : Normal serum creatinine level ( SCr = 120mol/L ) creatinine clearance rate ( CCr = 60 ml/min ) ; 9 . Hepatic function : Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level less equal 2.0 time upper limit normal ( ULN ) . Serum alkaline phosphatase ( ALP ) level less equal four time upper limit normal value . Serum total bilirubin level less equal 1.5 time upper limit normal value ; 10 . Hematopoietic function : White blood cell count ( WBC ) equal 4000 / μL , neutrophil ( ANC ) absolute count equal 1500 / μ L , platelet count equal 100000/ μ L , hemoglobin equal 10.0 g / dl . 1 . Surgery Left thoracic transhiatal approach , whereby complete lymphadenectomy achieve ; 2 . Patients experience severe postoperative complication thus , unable tolerate adjuvant therapy ; 3 . Patients concommitant malignant tumor ; 4 . Patients abnormal coagulation function , bleed tendency ( active peptic ulcer ) currently receive thrombolysis anticoagulation therapy ; 5 . Severe cardiac comorbidities , include congestive heart failure , uncontrolled cardiac arrhythmia , unstable angina pectoris , myocardial infarction within six month , severe heart valve disease , intractable hypertension ; 6 . Severe hepatic renal insufficiency ; 7 . Poor mental status mental disorder , poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>adjuvant radiotherapy</keyword>
	<keyword>lymph node metastasis</keyword>
	<keyword>surgery</keyword>
	<keyword>squamous cell carcinoma</keyword>
</DOC>